期刊
MOLECULAR CANCER THERAPEUTICS
卷 6, 期 4, 页码 1433-1439出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1535-7163.MCT-06-0677
关键词
-
类别
In vitro and in vivo studies have shown that 1 alpha,25-dihydroxyvitamin D-3 [1,25(OH)(2)D-3] inhibits angiogenesis in cancer. Ne now examined whether the antiangiogenic effects of 1,25(OH)(2)D-3 are mediated by the hypoxia-inducible factor (HIF)-1 pathway. Our results showed that 1,25(OH)21)3 reduces the protein expression of both the regulated HIF-1 alpha subunit and the vascular endothelial growth fa,tor (VEGF) in various human cancer cells. 1,25(OH)21)3 also inhibited HIF-1 transcriptional activity (measured by reporter gene assay) as well as HIF-1 target genes, including VEGF, ET-1, and Glut-1. We also showed that 1,25(OH)2D3 inhibits cell proliferation under hypoxia. Using HIF. 1 a knockout colon cancer cells, we show that the inhibition of the hypoxia-induced VEGF by 1,25(OH)21)3 is mediated through a HIF-dependent pathway. Because HIF-1 is a major positive contributor in human tumorigenesis and angiogenesis, we believe that its inhibition by 1,25(OH)2D3 strengthens the rationale to use vitamin D and its low-calcemic analogues in cancer chemoprevention and therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据